Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.297 USD | -3.85% | -4.72% | -46.00% |
Business Summary
Number of employees: 4
Managers
Managers | Title | Age | Since |
---|---|---|---|
Michael Poirier
CEO | Chief Executive Officer | 68 | 19-12-31 |
Christopher Lotz
DFI | Director of Finance/CFO | 59 | 01-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kurt Kruger
BRD | Director/Board Member | 68 | 19-12-31 |
Sidney Emery
BRD | Director/Board Member | 74 | 20-12-06 |
Michael Poirier
CEO | Chief Executive Officer | 68 | 19-12-31 |
Ira Ritter
BRD | Director/Board Member | 75 | 07-12-31 |
Director/Board Member | 49 | 19-12-31 | |
Richard David
BRD | Director/Board Member | 64 | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 6,307,371 | 5,580,883 ( 88.48 %) | 0 | 88.48 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.00% | 1.95M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- QLGN Stock
- Company Qualigen Therapeutics, Inc.